Pulido-Perez Patricia, Torres-Rasgado Enrique, Pérez-Fuentes Ricardo, Rosales-Encina José Luis, Rodríguez-Antolín Jorge, Romero Jose R
Doctorate in Biological Science, Autonomous University of Tlaxcala, Mexico; Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA; Center for Biomedical Research East, Mexican Social Security Institute of Puebla, Mexico; Department of Infectomics and Molecular Pathogenesis, Center for Research and Advanced Studies, National Polytechnic Institute, Mexico.
Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA; Center for Biomedical Research East, Mexican Social Security Institute of Puebla, Mexico; Faculty of Medicine, Autonomous University of Puebla, Mexico.
J Diabetes Complications. 2021 Sep;35(9):107974. doi: 10.1016/j.jdiacomp.2021.107974. Epub 2021 Jun 19.
Evidence implicates tumor necrosis factor (TNF) in the pathophysiology of Type 2 Diabetes (T2D) through unclear mechanisms. We hypothesized that disordered glycemic control leads to TNF activation and increases in soluble-TNF (sTNF) and its receptors-1 (sTNFR1) and -2 (sTNFR2).
We characterized 265 T2D and non-diabetic Latin American subjects and assessed the relationship between the TNF system and fasting plasma glucose (FPG), hemoglobin-A1C (A1C), insulin (FPI), C-peptide and HOMA-Beta.
sTNF and sTNFR2 but not sTNFR1 levels were higher in T2D than non-diabetics (P<0.0001). In T2D, sTNFR2 was associated with A1C and C-peptide (R=0.354, b=0.504, P<0.0001; b=0.167, P=0.049). Also, T2D patients with disordered glycemic control had increased sTNFR2 levels that correlated with FPG (Rho:0.393, P<0.001), A1C (Rho:0.451, P<0.001) and HOMA-Beta (Rho:-0.308, P=0.005); events not observed in T2D patients with adequate glycemic control. Furthermore, sex-based comparative analyses of T2D patients showed that women compared to men had higher sTNFR2 levels (P=0.017) that correlated with FPG, A1C, FPI and HOMA-Beta.
Disordered glycemic control is associated with sTNF and sTNFR2. sTNFR2 levels were higher in T2D women than men. Thus, increased sTNFR2 levels may be an important biomarker for disordered glucose and inflammatory complications in T2D patients and women in particular.
有证据表明肿瘤坏死因子（TNF）通过不明机制参与2型糖尿病（T2D）的病理生理过程。我们推测血糖控制紊乱会导致TNF激活，可溶性TNF（sTNF）及其受体-1（sTNFR1）和-2（sTNFR2）水平升高。
我们对265名拉丁裔T2D患者和非糖尿病患者进行了特征分析，并评估了TNF系统与空腹血糖（FPG）、糖化血红蛋白（A1C）、胰岛素（FPI）、C肽和HOMA-β之间的关系。
T2D患者的sTNF和sTNFR2水平高于非糖尿病患者，但sTNFR1水平无差异（P<0.0001）。在T2D患者中，sTNFR2与A1C和C肽相关（R=0.354，b=0.504，P<0.0001；b=0.167，P=0.049）。此外，血糖控制紊乱的T2D患者sTNFR2水平升高，与FPG（Rho:0.393，P<0.001）、A1C（Rho:0.451，P<0.001）和HOMA-β（Rho:-0.308，P=0.005）相关；而血糖控制良好的T2D患者未观察到这些情况。此外，对T2D患者进行的基于性别的比较分析显示，女性的sTNFR2水平高于男性（P=0.017），且与FPG、A1C、FPI和HOMA-β相关。
血糖控制紊乱与sTNF和sTNFR2相关。T2D女性患者的sTNFR2水平高于男性。因此，sTNFR2水平升高可能是T2D患者尤其是女性血糖紊乱和炎症并发症的重要生物标志物。
